Polyguluronate simulations shed light onto the therapeutic action of OligoG CF-5/20

Bioorg Med Chem. 2022 Oct 15:72:116945. doi: 10.1016/j.bmc.2022.116945. Epub 2022 Jul 26.

Abstract

Chronic mucoid P. aeruginosa cystic fibrosis (CF) lung infections are associated with the development of a biofilm composed of anionic acetylated exopolysaccharide (EPS) alginate, electrostatically stabilised by extracellular Ca2+ ions. OligoG CF-5/20, a low molecular weight guluronate rich oligomer, is emerging as a novel therapeutic capable of disrupting mature P. aeruginosa biofilms. However, its method of therapeutic action on the mucoid biofilm EPS is not definitively known at a molecular level. This work, utilising molecular dynamics (MD) and Density-Functional Theory (DFT), has revealed that OligoG CF-5/20 interaction with the EPS is facilitated solely through bridging Ca2+ ions, which are not liberated from their native EPS binding sites upon OligoG CF-5/20 dispersal, suggesting that OligoG CF-5/20 does not cause disruptions to mature P. aeruginosa biofilms through breaking EPS-Ca2+-EPS ionic cross-links. Rather it is likely that the therapeutic activity arises from sequestering free Ca2+ ions and preventing further Ca2+ induced EPS aggregation.

Keywords: Density-functional theory; Molecular dynamics; Mucoid biofilms; OligoG CF-5/20; P. aeruginosa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alginates / chemistry
  • Alginates / metabolism
  • Alginates / pharmacology
  • Biofilms
  • Cystic Fibrosis*
  • Humans
  • Polysaccharides, Bacterial
  • Pseudomonas Infections*
  • Pseudomonas aeruginosa / metabolism

Substances

  • Alginates
  • polyguluronic acid
  • Polysaccharides, Bacterial
  • oligoG CF-5-20